Home » Authors » James Etheridge

Articles by James Etheridge

Novagali Launches Phase I Trial, Negotiates Second-Round Funds

Dec. 24, 2003

By James Etheridge

Novagali Launches Phase I Trial, Negotiates Second-Round Funds

Dec. 24, 2003

By James Etheridge

UroGene, SGX To Develop Kinase Inhibitors For Urological Cancers

Dec. 24, 2003

By James Etheridge

Faust Pharmaceuticals Acquires Euroclide, Seeks EUR12M Funding

Dec. 17, 2003

By James Etheridge

Innate Pharma, Novo Nordisk In Cancer Immunotherapy Deal

Dec. 17, 2003

By James Etheridge

Faust Pharmaceuticals Acquires Euroclide, Seeks EUR12M Funding

Dec. 17, 2003

By James Etheridge

Innate Pharma, Novo Nordisk In Cancer Immunotherapy Deal

Dec. 17, 2003

By James Etheridge

French Food Safety Agency Has Bt11 Sweet Corn Doubts

Dec. 10, 2003

By James Etheridge

French Food Safety Agency Has Bt11 Sweet Corn Doubts

Dec. 10, 2003

By James Etheridge

Innogenetics Plans To Raise EUR39M Through Public Offering

Dec. 3, 2003

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...